Enliven Therapeutics raises $90M in PIPE financing for blood cancer/solid tumor lead programs and Phase 1 trial of ELVN-001.
Enliven Therapeutics secures $90M in PIPE financing from new & existing investors, including Commodore Capital, Fairmount, and Venrock Healthcare Capital Partners. The funds will strengthen its balance sheet & support clinical milestones for lead programs ELVN-001 & ELVN-002, both targeting blood cancers & solid tumors. The company is currently enrolling patients for a Phase 1 trial of ELVN-001.
March 19, 2024
5 Articles